BeOne Medicines (ONC) Competitors $343.87 -1.30 (-0.38%) As of 10/3/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONC vs. SNY, GSK, TAK, ARGX, INSM, BNTX, TEVA, GMAB, SMMT, and ASNDShould you be buying BeOne Medicines stock or one of its competitors? The main competitors of BeOne Medicines include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. BeOne Medicines vs. Its Competitors Sanofi GSK Takeda Pharmaceutical argenex Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Do analysts rate ONC or SNY? BeOne Medicines currently has a consensus price target of $336.30, indicating a potential downside of 2.20%. Sanofi has a consensus price target of $62.67, indicating a potential upside of 23.12%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90Sanofi 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media prefer ONC or SNY? In the previous week, Sanofi had 15 more articles in the media than BeOne Medicines. MarketBeat recorded 21 mentions for Sanofi and 6 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.96 beat Sanofi's score of 0.53 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility and risk, ONC or SNY? BeOne Medicines has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Is ONC or SNY more profitable? Sanofi has a net margin of 21.47% compared to BeOne Medicines' net margin of -3.89%. Sanofi's return on equity of 16.86% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-3.89% -1.22% -0.72% Sanofi 21.47%16.86%9.63% Do insiders and institutionals believe in ONC or SNY? 48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, ONC or SNY? Sanofi has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B9.89-$644.79M-$1.73-198.77Sanofi$44.46B2.81$6.02B$4.1612.24 SummarySanofi beats BeOne Medicines on 12 of the 17 factors compared between the two stocks. Get BeOne Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricBeOne MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.69B$2.63B$6.13B$10.58BDividend YieldN/A56.38%5.67%4.69%P/E Ratio-198.7724.2286.8826.71Price / Sales9.89726.66605.32131.81Price / CashN/A172.1237.9061.31Price / Book10.085.3412.556.55Net Income-$644.79M$32.92M$3.31B$277.50M7 Day Performance5.46%3.90%4.28%2.42%1 Month Performance0.61%8.79%6.90%8.63%1 Year PerformanceN/A-3.79%70.54%31.60% BeOne Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCBeOne Medicines1.5516 of 5 stars$343.87-0.4%$336.30-2.2%N/A$37.69B$3.81B-198.7711,000Analyst UpgradeSNYSanofi4.1882 of 5 stars$45.54+1.0%$62.67+37.6%-8.2%$110.67B$44.46B10.9582,878Analyst RevisionHigh Trading VolumeGSKGSK2.1777 of 5 stars$39.83+0.8%$37.38-6.2%+11.5%$80.40B$40.10B18.4468,629Dividend CutTAKTakeda Pharmaceutical1.6313 of 5 stars$14.74+0.6%N/A+1.3%$46.62B$30.09B49.1347,455ARGXargenex3.7095 of 5 stars$711.62+0.1%$789.20+10.9%+51.0%$43.52B$2.25B36.491,599Analyst ForecastINSMInsmed3.313 of 5 stars$137.03+1.1%$139.86+2.1%+117.5%$28.66B$398.11M-24.001,271News CoverageAnalyst ForecastBNTXBioNTech2.6877 of 5 stars$98.08flat$134.56+37.2%-14.0%$23.58B$2.98B-61.306,772Positive NewsTEVATeva Pharmaceutical Industries3.015 of 5 stars$18.30-0.3%$25.14+37.4%+14.4%$21.04B$16.63B-114.3836,830Analyst ForecastOptions VolumeGMABGenmab A/S4.1485 of 5 stars$29.07+0.8%$40.00+37.6%+42.9%$18.50B$3.12B14.612,682Trending NewsAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics3.0229 of 5 stars$20.95+3.4%$31.29+49.3%+12.3%$15.05BN/A-20.74110ASNDAscendis Pharma A/S3.2818 of 5 stars$191.99+1.2%$244.36+27.3%+43.0%$11.83B$490.75M-37.211,017Positive News Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives ASND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONC) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
